Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
Peer-reviewed article confirms the quality and robustness of clinical data and the good safety and durable efficacy of once daily oral ABX464 in moderate to severe ulcerative colitis (UC) patients Recruitment of subsequent phase 2b induction study in 254 patie...
The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences...
Funding to support U.S. commercial launch and global expansion February 16, 2021 08:00 AM Eastern Standard Time - DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the closing of an equity financing in which...
EnginZyme seeks to transform the $5 trillion chemical industry through the use of its enzyme-based platform, which combines the breadth and power of nature with the efficiencies of state-of-the-art chemical processing techniques February 11, 2021 01:00 AM Ea...
The Roche Venture Fund joins international investor syndicate, including co-lead investors Sofinnova Partners and AbbVie Ventures Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-back...
© 2020 Sofinnova Partners TERMS AND CONDITIONS